Santaris Pharma has inked a collaboration deal with Enzon Pharmaceuticals that is potentially worth more than $200 million. Enzon will pay Santaris $8 million up front to license two of Santaris's preclinical drug candidates and six RNA Antagonist candidates to be tested against oncology drug targets. Santaris retains European commercialization rights while Enzon gains the rights to the U.S. and non-European countries.
"This very important collaboration is in line with our strategic goal of advancing our presence in oncology while leveraging our access to proprietary new technologies," said Jeffrey H. Buchalter, Enzon's chairman and chief executive officer. "This partnership will greatly enhance our R&D pipeline with the addition of two new clinical programs in the next six-to-12 months and another six preclinical compounds entering the pipeline over the next few years."
- check out the release on the deal
ALSO: Cambridge Antibody Technology has acquired the experimental SS1P (renamed CAT-5001) from Enzon Pharmaceuticals. Release